A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects

• Drug: PF-06282999
  
  Solution, doses range from 20 to 200 mg, single dose
• Drug: Placebo
  
  Solution, single dose
• Drug: PF-06282999
  
  Methylcellulose suspension, doses range 125 to 500 mg, single dose
• Drug: Placebo
  
  suspension, single dose
• Drug: PF-06282999
  
  Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
• Drug: PF-06282999
  
  Methylcellulose or simethicone suspension, 500 mg dose, single dose
• Drug: PF-06282999
  
  Simethicone or methylcellulose suspension, up to 1500 mg, single dose

• Experimental: Cohort 1
  
  Interventions:
  

  • Drug: PF-06282999
  • Drug: Placebo
• Experimental: Cohort 2
  
  Interventions:
  

  • Drug: PF-06282999
  • Drug: Placebo
• Experimental: Cohort 3
  
  Interventions:
  

  • Drug: PF-06282999
  • Drug: Placebo
• Experimental: Cohort 4
  
  Interventions:
  

  • Drug: PF-06282999
  • Drug: Placebo
• Experimental: Cohort 5
  
  Interventions:
  

  • Drug: PF-06282999
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Women must be of non-childbearing potential.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including clinically significant drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of ?1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.